NetraMark Holdings Inc
AIAI.TO
Toronto Stock Exchange0.67
CAD
-0.05
- -
NetraMark Holdings Inc
AIAI.TO
(Toronto Stock Exchange)
Recent
price
0.67
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- NetraMark Holdings Inc. is an artificial intelligence company focused on developing machine learning solutions for the pharmaceutical and clinical research industries; it develops and commercializes the NetraAI platform, a topology-based analytics system designed to parse clinical and patient datasets into statistically related subgroups to support clinical trial design, trial analysis, and precision medicine applications. The company’s product and service offering includes AI-powered precision analytics; clinical trial data analysis; dataset segmentation and subgroup discovery; support for pharmaceutical research and development; commercial deployments through direct pharmaceutical engagements and contract research organization channels; and related scientific collaboration and validation activities. Founded in 2016 and headquartered in Toronto, Ontario, Canada, NetraMark serves pharmaceutical companies, biopharmaceutical companies, and clinical research organizations across North America and other international markets through its commercial and research programs. The company’s head office is located at 1655 Dupont Street, Suite 101, Toronto, Ontario, with a registered office in Vancouver, British Columbia. Recent developments include record fiscal 2026 contract bookings of approximately C$3.4 million, up 645% from the prior annual high, driven by expanded direct pharmaceutical engagements and its first commercial CRO partnership. NetraMark also reported a late-stage biopharmaceutical clinical-trial analysis agreement, a Phase 2 analysis contract through an established CRO, and continued expansion of the NetraAI platform across pharmaceutical and clinical-research workflows. Additional strategic changes in 2026 include a C$3.5 million private placement, uplisting to the Toronto Stock Exchange, appointment of Kevin Felix as strategic advisor, and the addition of Dr. Keith Fournier to the board of directors.